some patients with NSCLC were not, including patients diagnosed with NSCLC due to symptomatic brain metastases. Our results are, therefore, biased toward the null. Despite these limitations, this study strongly supports further investigation into MRI screening of the brain among select patients with metastatic breast cancer.
1. Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11) :1511-1521. Table 1 . Women had significantly higher rates of all-grade nausea, vomiting, constipation, cramping, stomatitis, cholinergic syndrome, lethargy, alopecia, leukopenia, neutropenia and anemia. Overall toxic effects and differences between women and men were numerically increased with FOLFIRI ( Table 2 ). Significantly higher rates of all-grade constipation, nausea, vomiting, alopecia, leukopenia, neutropenia, and anemia in women were observed regardless of treatment (fluorouracil/leucovorin or FOLFIRI). The significantly higher risk for leukopenia, anemia, alopecia, and vomiting for women was not affected by age. Grade 3 or 4 AEs significantly more frequent in women in pooled treatment arms (Table 1) were alopecia, stomatitis, diarrhea, nausea, leukopenia, neutropenia, and anemia. Under treatment with FOLFIRI, but not fluorouracil and leucovorin, significant differences between men and women were seen for grade 3 or 4 alopecia, stomatitis, diarrhea, and lethargy ( Table 2 ). The higher incidence of grade 3 or 4 neutropenia in women treated with FOLFIRI was independent of age and BMI. Dose reductions were more frequent in women vs men (341 [25.9%] vs 279 [16.8%]; P < .001), especially under treatment with FOLFIRI.
Discussion | This analysis is the largest to date that systematically addresses the association of sex with all types of toxic effects of standard fluorouracil with or without irinotecan chemotherapy in CRC. It demonstrates a statistically significant and clinically relevant greater risk of nonhematological and objectively measurable hematological AEs in women. Female sex has previously been identified as a risk factor for irinotecan-induced neutropenia. 4 As UGT1A1 polymorphisms do not vary with sex, 5 they cannot explain the observed differences in toxic effects caused by irinotecan. These differences must be either pharmacokinetic, as demonstrated for fluorouracil, or pharmacodynamic. In an age of personalized medicine, and also considering growing knowledge about sex-related differences in molecular profiles and disease biology, 6 the potential effect of sex on efficacy and toxic effects of systemic treatments in oncology deserves more awareness and further investigation. Drug targets, but also the optimal dose necessary to hit a target with an acceptable level of toxic effects, may be different between men and women. 
